Developer docs
API playgroundTry for free, no card

Search company profiles

Transition Bio

Full company profile

uuid0000ej9

Namestring
Transition Bio
Legal namestring
Transition Bio, LLC
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Transition Bio is a privately held drug discovery platform company founded in 2020 and headquartered in Cambridge, Massachusetts with an operating entity in Cambridge, United Kingdom. The company is built around biomolecular condensate biology, a relatively new frontier in drug discovery focused on the membraneless cellular compartments that organize protein interactions and drive disease when dysregulated. Transition Bio develops the Condensomics platform, an end-to-end discovery engine that combines proprietary droplet microfluidics (PhaseScan high-throughput molecular screening), state-of-the-art cellular imaging, and a machine learning/AI engine trained on proprietary datasets. The platform is designed to identify and optimize small molecule therapeutics against intrinsically disordered proteins and other condensate-modulating targets that traditional structure-based drug discovery has been unable to address. The company positions itself as tackling targets historically considered "undruggable," with disclosed pipeline programs in MYC-driven cancers (lead YTHDC1 inhibitor program across AML, SCLC, and NSCLC) and neurodegenerative disease (TDP-43 program partnered with Voyager Therapeutics for ALS and frontotemporal dementia).

The company's core technology assets were developed through exclusive academic relationships with Harvard University's Weitz Laboratory and the University of Cambridge's Knowles Laboratory. Scientific co-founders include David Weitz (Harvard, h-index 218, NAS/NAE member), Tuomas Knowles (Cambridge, 300+ publications), Peter St George-Hyslop (Columbia, leading Alzheimer's researcher), and Sarah Teichmann (Wellcome Sanger Institute, co-leader of the Human Cell Atlas). Operating leadership includes Executive Chairman G. Kelly Martin (former CEO of Radius Health and Elan Corporation), CEO Gregory Miller, Co-President and CSO Shilpi Arora (formerly VP at Exo Therapeutics), and Co-President and COO Martin Kulander (formerly Senior/Executive Director at AstraZeneca). The board includes Voyager Therapeutics CEO Alfred W. Sandrock Jr., former CFO of Cerevel and Sangamo Kathy Yi, and a Northpond Ventures representative.

Transition Bio operates as a B2B partnership-driven drug discovery business rather than a product company. Revenue mechanics rely on milestone payments and royalties earned through co-development agreements with pharmaceutical and biotechnology partners. The company conducts discovery and lead optimization through development candidate nomination, at which point the partner typically obtains an exclusive license option for further development and commercialization. The most material disclosed partnership is the November 2025 Voyager Therapeutics collaboration on TDP-43, valued at up to $500 million in potential milestone payments plus royalties. Strategic investors include Bristol Myers Squibb, which participated in the 2022 Series A and represents a potential pharma partnership channel in addition to financial backing. To date, Transition Bio has raised approximately $63 million in disclosed funding (an undisclosed seed in 2020, a $50 million Series A in 2022 led by Northpond Ventures, and approximately $13.3 million in additional financing in October 2024), and has not disclosed product revenue.

Short descriptiontext

Transition Bio is a Cambridge, MA-based drug discovery platform company developing the Condensomics platform, combining droplet microfluidics, cellular imaging, and proprietary AI/ML to discover small molecules targeting biomolecular condensates and intrinsically disordered proteins for pharmaceutical and biotech partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, biomolecular condensates, droplet microfluidics, small molecule therapeutics, intrinsically disordered proteins
Industry5 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Transition Bio generates revenue through partnership agreements where it receives milestone payments and royalties. The company is responsible for discovery and optimization until nomination of a development candidate, after which partners gain exclusive license options. The Voyager collaboration includes up to $500 million in milestone payments plus royalties.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Transition Bio operates a drug discovery platform that partners with pharmaceutical and biotech companies to identify and optimize small molecule drug candidates against biomolecular condensate and intrinsically disordered protein targets. Through its proprietary Condensomics platform, which combines droplet microfluidics, advanced cellular imaging, and machine learning/AI, the company conducts target identification, hit identification, mechanism-of-action studies, and lead optimization through development candidate nomination, after which partners assume further development and commercialization via licensing arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Up to $500 million in milestone payments plus royalties from Voyager partnership
+1 more record
Product overview1 text field

Transition Bio offers a unified Condensomics™ Platform for biomolecular condensate drug discovery, comprising PhaseScan screening technology (microfluidics-based high throughput molecular screening), a Machine Learning/AI engine (proprietary models for optimization), and pipeline programs including the YTHDC1 inhibitor program (lead oncology program targeting MYC-driven cancers) and TDP-43 collaboration (with Voyager for ALS/FTD). The platform integrates droplet microfluidics and cellular imaging with ML/AI to identify and optimize chemical matter for drug discovery.

Product and service3 records
1Condensomics Platform
CategoryDrug Discovery Platform
Description

End-to-end condensate drug discovery platform that combines droplet microfluidics and state-of-the-art cellular imaging with machine learning and AI to discover and optimize small molecule drug candidates against biomolecular condensates and intrinsically disordered proteins. Offered to pharmaceutical and biotech partners through co-development agreements leading to development candidate nomination and licensing.

2YTHDC1 Inhibitor Program
CategoryPipeline Program (Oncology)
Description

Lead small-molecule inhibitor program targeting YTHDC1 for MYC-driven cancers, including applications in small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Lead candidate has demonstrated robust efficacy in MYC-driven cancers as a single agent and in combination with standard-of-care therapies.

3TDP-43 Drug Discovery Collaboration with Voyager Therapeutics
CategoryPipeline Program (Neurodegenerative Disease)
Description

Co-development program with Voyager Therapeutics to discover and develop small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio handles discovery and optimization through development candidate nomination, after which Voyager gains an exclusive license option. Deal value up to $500 million in milestone payments plus royalties for Transition Bio.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Collaboration to discover small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio is responsible for discovery and optimization until nomination of a development candidate. Voyager gains exclusive license option upon candidate nomination. Deal includes up to $500M in milestone payments plus royalties for Transition Bio. The partnership addresses therapeutic challenges of targeting TDP-43, a protein involved in several neurodegenerative diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct competitor focused on discovering drugs that modulate biomolecular condensates. Both companies target intrinsically disordered proteins and condensate biology, addressing the same scientific thesis around condensates as druggable systems.

2Faze Medicines
TypeDirect peer
Description

Biomolecular condensate therapeutics company developing small-molecule condensate modulators. Directly comparable scientific platform and therapeutic thesis to Transition Bio's Condensomics engine.

3Nereid Therapeutics
TypeDirect peer
Description

Condensate biology-focused drug discovery company. Shares the same core scientific premise of targeting biomolecular condensates for difficult disease targets, with overlapping leadership and academic network.

TypeDirect peer
Description

AI/ML-driven drug discovery platform combining machine learning with high-throughput biology. Comparable platform-based business model targeting traditional and novel targets via proprietary computational infrastructure.

TypeDirect peer
Description

Public AI-driven drug discovery platform combining high-throughput experimental biology with ML. Comparable partnership-driven model and platform approach to small-molecule discovery.

TypeDirect peer
Description

AI-driven precision medicine company with end-to-end small-molecule discovery platform. Direct peer in AI-augmented drug discovery serving pharma partners via licensing and co-development deals.

7Isomorphic Labs
TypeBroad incumbent
Description

Alphabet/DeepMind spinout applying AlphaFold-derived AI to drug discovery. Well-capitalized competitor in computational drug discovery with broader portfolio focus and strategic pharma partnerships (Novartis, Lilly).

TypeDirect peer
Description

AI-driven small-molecule drug discovery company using proprietary ML for hit identification and lead optimization. Comparable partnership-based GTM motion serving pharma collaborators across multiple targets.

TypeBroad incumbent
Description

Public computational chemistry and drug discovery company with physics-based simulation platform. Comparable technology-driven approach to small-molecule discovery and well-established pharma partnerships.

TypeEmerging player
Description

AI-driven small-molecule discovery platform combining high-throughput experimentation with proprietary ML. Comparable platform approach at similar stage, focused on internal pipeline plus partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transition Bio

Drug Discovery Servicestransitionbio.com

Transition Bio is a Cambridge, MA-based drug discovery platform company developing the Condensomics platform, combining droplet microfluidics, cellular imaging, and proprietary AI/ML to discover small molecules targeting biomolecular condensates and intrinsically disordered proteins for pharmaceutical and biotech partners.

What Transition Bio does

Transition Bio is a privately held drug discovery platform company founded in 2020 and headquartered in Cambridge, Massachusetts with an operating entity in Cambridge, United Kingdom. The company is built around biomolecular condensate biology, a relatively new frontier in drug discovery focused on the membraneless cellular compartments that organize protein interactions and drive disease when dysregulated. Transition Bio develops the Condensomics platform, an end-to-end discovery engine that combines proprietary droplet microfluidics (PhaseScan high-throughput molecular screening), state-of-the-art cellular imaging, and a machine learning/AI engine trained on proprietary datasets. The platform is designed to identify and optimize small molecule therapeutics against intrinsically disordered proteins and other condensate-modulating targets that traditional structure-based drug discovery has been unable to address. The company positions itself as tackling targets historically considered "undruggable," with disclosed pipeline programs in MYC-driven cancers (lead YTHDC1 inhibitor program across AML, SCLC, and NSCLC) and neurodegenerative disease (TDP-43 program partnered with Voyager Therapeutics for ALS and frontotemporal dementia).

The company's core technology assets were developed through exclusive academic relationships with Harvard University's Weitz Laboratory and the University of Cambridge's Knowles Laboratory. Scientific co-founders include David Weitz (Harvard, h-index 218, NAS/NAE member), Tuomas Knowles (Cambridge, 300+ publications), Peter St George-Hyslop (Columbia, leading Alzheimer's researcher), and Sarah Teichmann (Wellcome Sanger Institute, co-leader of the Human Cell Atlas). Operating leadership includes Executive Chairman G. Kelly Martin (former CEO of Radius Health and Elan Corporation), CEO Gregory Miller, Co-President and CSO Shilpi Arora (formerly VP at Exo Therapeutics), and Co-President and COO Martin Kulander (formerly Senior/Executive Director at AstraZeneca). The board includes Voyager Therapeutics CEO Alfred W. Sandrock Jr., former CFO of Cerevel and Sangamo Kathy Yi, and a Northpond Ventures representative.

Transition Bio operates as a B2B partnership-driven drug discovery business rather than a product company. Revenue mechanics rely on milestone payments and royalties earned through co-development agreements with pharmaceutical and biotechnology partners. The company conducts discovery and lead optimization through development candidate nomination, at which point the partner typically obtains an exclusive license option for further development and commercialization. The most material disclosed partnership is the November 2025 Voyager Therapeutics collaboration on TDP-43, valued at up to $500 million in potential milestone payments plus royalties. Strategic investors include Bristol Myers Squibb, which participated in the 2022 Series A and represents a potential pharma partnership channel in addition to financial backing. To date, Transition Bio has raised approximately $63 million in disclosed funding (an undisclosed seed in 2020, a $50 million Series A in 2022 led by Northpond Ventures, and approximately $13.3 million in additional financing in October 2024), and has not disclosed product revenue.

Transition Bio firmographics

Firmographics
Name
Transition Bio
Legal name
Transition Bio, LLC
Website
https://transitionbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Transition Bio is a Cambridge, MA-based drug discovery platform company developing the Condensomics platform, combining droplet microfluidics, cellular imaging, and proprietary AI/ML to discover small molecules targeting biomolecular condensates and intrinsically disordered proteins for pharmaceutical and biotech partners.
Ownership category
akta.pro rank

Transition Bio industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery platform
  • Biomolecular condensates
  • Droplet microfluidics
  • Small molecule therapeutics
  • Intrinsically disordered proteins

Where Transition Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Transition Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Transition Bio generates revenue through partnership agreements where it receives milestone payments and royalties. The company is responsible for discovery and optimization until nomination of a development candidate, after which partners gain exclusive license options. The Voyager collaboration includes up to $500 million in milestone payments plus royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Transition Bio product offering

Product offering

Core offering

Transition Bio operates a drug discovery platform that partners with pharmaceutical and biotech companies to identify and optimize small molecule drug candidates against biomolecular condensate and intrinsically disordered protein targets. Through its proprietary Condensomics platform, which combines droplet microfluidics, advanced cellular imaging, and machine learning/AI, the company conducts target identification, hit identification, mechanism-of-action studies, and lead optimization through development candidate nomination, after which partners assume further development and commercialization via licensing arrangements.

Product overview

Transition Bio offers a unified Condensomics™ Platform for biomolecular condensate drug discovery, comprising PhaseScan screening technology (microfluidics-based high throughput molecular screening), a Machine Learning/AI engine (proprietary models for optimization), and pipeline programs including the YTHDC1 inhibitor program (lead oncology program targeting MYC-driven cancers) and TDP-43 collaboration (with Voyager for ALS/FTD). The platform integrates droplet microfluidics and cellular imaging with ML/AI to identify and optimize chemical matter for drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Condensomics Platform End-to-end condensate drug discovery platform that combines droplet microfluidics and state-of-the-art cellular imaging with machine learning and AI to discover and optimize small molecule drug candidates against biomolecular condensates and intrinsically disordered proteins. Offered to pharmaceutical and biotech partners through co-development agreements leading to development candidate nomination and licensing.
  • YTHDC1 Inhibitor Program Lead small-molecule inhibitor program targeting YTHDC1 for MYC-driven cancers, including applications in small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Lead candidate has demonstrated robust efficacy in MYC-driven cancers as a single agent and in combination with standard-of-care therapies.
  • TDP-43 Drug Discovery Collaboration with Voyager Therapeutics Co-development program with Voyager Therapeutics to discover and develop small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio handles discovery and optimization through development candidate nomination, after which Voyager gains an exclusive license option. Deal value up to $500 million in milestone payments plus royalties for Transition Bio.

Quantifiable outcome

  • Up to $500 million in milestone payments plus royalties from Voyager partnership
  • +1 more outcomes

Companies that use Transition Bio

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Transition Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Transition Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Voyager TherapeuticscoreStrategic or Co-development Partner · 10 November 2025Collaboration to discover small molecules targeting TDP-43 for ALS and frontotemporal dementia. Transition Bio is responsible for discovery and optimization until nomination of a development candidate. Voyager gains exclusive license option upon candidate nomination. Deal includes up to $500M in milestone payments plus royalties for Transition Bio. The partnership addresses therapeutic challenges of targeting TDP-43, a protein involved in several neurodegenerative diseases.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Transition Bio competitors and assessment

Company assessment

Direct peers

  • Dewpoint Therapeutics: Closest direct competitor focused on discovering drugs that modulate biomolecular condensates. Both companies target intrinsically disordered proteins and condensate biology, addressing the same scientific thesis around condensates as druggable systems.
  • Faze Medicines: Biomolecular condensate therapeutics company developing small-molecule condensate modulators. Directly comparable scientific platform and therapeutic thesis to Transition Bio's Condensomics engine.
  • Nereid Therapeutics: Condensate biology-focused drug discovery company. Shares the same core scientific premise of targeting biomolecular condensates for difficult disease targets, with overlapping leadership and academic network.
  • Insitro: AI/ML-driven drug discovery platform combining machine learning with high-throughput biology. Comparable platform-based business model targeting traditional and novel targets via proprietary computational infrastructure.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput experimental biology with ML. Comparable partnership-driven model and platform approach to small-molecule discovery.
  • Exscientia: AI-driven precision medicine company with end-to-end small-molecule discovery platform. Direct peer in AI-augmented drug discovery serving pharma partners via licensing and co-development deals.
  • Atomwise: AI-driven small-molecule drug discovery company using proprietary ML for hit identification and lead optimization. Comparable partnership-based GTM motion serving pharma collaborators across multiple targets.

Broad incumbents

  • Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-derived AI to drug discovery. Well-capitalized competitor in computational drug discovery with broader portfolio focus and strategic pharma partnerships (Novartis, Lilly).
  • Schrödinger: Public computational chemistry and drug discovery company with physics-based simulation platform. Comparable technology-driven approach to small-molecule discovery and well-established pharma partnerships.

Emerging players

  • Terray Therapeutics: AI-driven small-molecule discovery platform combining high-throughput experimentation with proprietary ML. Comparable platform approach at similar stage, focused on internal pipeline plus partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Transition Bio social profiles

Digital presence

Transition Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transition Bio leadership team

Management profile

Number of profiles

Profiles13 records

Transition Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transition Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transition Bio

What does Transition Bio do?

Transition Bio operates a drug discovery platform that partners with pharmaceutical and biotech companies to identify and optimize small molecule drug candidates against biomolecular condensate and intrinsically disordered protein targets. Through its proprietary Condensomics platform, which combines droplet microfluidics, advanced cellular imaging, and machine learning/AI, the company conducts target identification, hit identification, mechanism-of-action studies, and lead optimization through development candidate nomination, after which partners assume further development and commercialization via licensing arrangements.

Is Transition Bio a public or private company?

Transition Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Transition Bio founded?

Transition Bio was founded in 2020. It employs 11 to 50 people.

Where is Transition Bio based?

Transition Bio is headquartered in Cambridge, United States, in the North America region.

How does Transition Bio make money?

One revenue line is on record: licensing and Milestone Payments.

Who are Transition Bio's main competitors?

Direct peers on record are Dewpoint Therapeutics, Faze Medicines, Nereid Therapeutics, Insitro, Recursion Pharmaceuticals, Exscientia and Atomwise. Broad incumbents are Isomorphic Labs and Schrödinger. Terray Therapeutics is listed as an emerging player.

Does Transition Bio have an API?

No public API is recorded for Transition Bio.

What industry is Transition Bio in?

Transition Bio's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageTransition Bio Partners with the Little Warrior FoundationTransition Bio received a $750,000 grant from the Little Warrior Foundation to accelerate research on Ewing Sarcoma, targeting the EWS-FLI1 protein. The partnership aims to create the first targeted therapy for this aggressive pediatric cancer, leveraging Transition Bio's microfluidics and machine learning platform.MorningstarTransition Bio Partners with the Little Warrior FoundationTransition Bio received a $750,000 grant from the Little Warrior Foundation to accelerate research on Ewing Sarcoma. The partnership aims to create a targeted therapy for the disease, leveraging Transition Bio's microfluidics and machine learning tools to study the EWS-FLI1 protein.BioSpaceVoyager Reports Third Quarter 2025 Financial and Operating ResultsVoyager Therapeutics reported third quarter 2025 financial results showing a net loss of $27.9 million, compared to $9.0 million in the prior year period, with collaboration revenue declining to $13.4 million from $24.6 million primarily due to reduced revenue recognition under the 2022 Novartis agreement. The company introduced its Voyager NeuroShuttle discovery program and entered a collaboration with Transition Bio to develop small molecule treatments for ALS and frontotemporal dementia targeting TDP-43 pathology, while also receiving notification that Novartis discontinued two discovery-stage programs with rights reverting to Voyager. Voyager maintained a cash position of $229 million with runway into 2028.BioSpaceTransition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaTransition Bio and Voyager Therapeutics have entered into a drug discovery collaboration and license option agreement to develop novel small molecules targeting TDP-43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Transition Bio received a single-digit million-dollar upfront payment and is eligible for potential milestones totaling up to $500 million plus high single-digit to low double-digit royalties on net sales. Voyager will have the option to license worldwide exclusive rights to develop and commercialize the program following development candidate nomination.GlobeNewswireVoyager Reports Third Quarter 2025 Financial and Operating ResultsVoyager Therapeutics reported Q3 2025 results with a net loss of $27.9 million and collaboration revenue of $13.4 million. The company ended the quarter with $229 million in cash, maintaining a runway into 2028. It also introduced the Voyager NeuroShuttle platform and entered a collaboration with Transition Bio for ALS and FTD.GlobeNewswireTransition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal DementiaTransition Bio and Voyager Therapeutics announced a collaboration to develop small molecules targeting TDP-43, a protein involved in neurodegenerative diseases such as ALS and FTD. Transition Bio will handle discovery and optimization, with Voyager earning licensing rights upon development candidate nomination, potentially resulting in up to $500M in milestone payments.Stock TitanTransition Bio, Voyager partner on ALS/FTD; up to $500MTransition Bio and Voyager Therapeutics have entered into a drug discovery collaboration and license option agreement to develop small molecule therapeutics targeting TDP-43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Transition Bio will lead discovery and optimization work through development candidate nomination, after which Voyager gains an option to license worldwide exclusive rights. Transition Bio received a single-digit million-dollar upfront payment and is eligible for potential milestone and royalty payments totaling up to $500 million.MarketScreenerVoyager Therapeutics Enters Collaboration With Transition Bio on ALS, FTD Drug DiscoveryVoyager Therapeutics, Inc. announced a collaboration with Transition Bio to develop drugs for ALS and FTD. The company's pipeline includes gene therapies for ALS, among other neurodegenerative diseases.VC News DailyTransition Bio Closes $50M Series A FinancingTransition Bio, a Cambridge-based microfluidics-driven drug discovery platform company, announced the closing of a $50 million Series A financing round. The round was led by Northpond Ventures with participation from Taiho Ventures, Bristol Myers Squibb, Magnetic Ventures, and existing investor Lifeforce Capital. The funding will support the company's platform that uses biophysical sciences and artificial intelligence to map and modulate biomolecular condensates for drug discovery.